Ascletis Reports Positive Phase I Results for ASC5...
Category : Clinical Trial Update 29 September 2026Oral IL-17A Inhibitor Shows Positive Results in 28-Day Proof-of-Concept Study Ascletis Pharma Inc...
Clinical Trial Update
AI in Clinical Trials Market to Reach USD 7.32 Bil...
Category : Clinical Trial Update 28 September 2026Market Expected to Grow at 15.5% CAGR From 2026 to 2034 The global AI in Clinical Trials Market i...
Kodiak Sciences to Report Phase 3 DAYBREAK Results...
Category : Clinical Trial Update 28 September 2026Topline Results Will Evaluate Treatments for Wet Age-Related Macular Degeneration Kodiak Sciences...
Gossamer Bio submits NDA to US FDA for seralutinib...
Category : Clinical Trial Update 26 September 2026Gossamer Bio, Inc., a clinical-stage biopharmaceutical company focused on the development and commer...
Newron Provides Update on Phase 3 ENIGMA-TRS 2 Stu...
Category : Clinical Trial Update 26 September 2026Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical co...
Latest Newsletter Post
-
Takeda announces positive data from..
1 October 2026
-
Vanda Reports Positive Phase III Re..
30 September 2026
-
Airway Therapeutics Receives $1.9 M..
30 September 2026
-
Tolerance Bio Licenses TLB-33 From..
30 September 2026
-
Ascletis Reports Positive Phase I R..
29 September 2026
